Novartis Shares Plunge 10% Following Second Clinical Trial Failure in a Week

Key Facts

Amid rising pressure on the global pharmaceutical sector to deliver breakthrough treatments, Novartis faced a significant setback that rattled investor confidence. Shares of the company plummeted 10% after it announced that its experimental drug del-desiran failed in a late-stage clinical trial for myotonic dystrophy. According to reports, this failure raises concerns regarding the company's ability to sustain its growth pipeline through new therapeutic candidates.

This development marks the second major clinical disappointment for the company in a single week, following the earlier failure of the cardiovascular drug pelacarsen. Per market dynamics, back-to-back failures in late-stage trials are viewed as a significant negative catalyst for valuation. The successive nature of these setbacks has intensified scrutiny on the company's research and development efficiency compared to its industry peers.

Regarding price action, Novartis shares exhibited a sharp downward trend, though specific closing levels for September 8, 2026, remain unavailable in current data. Investors are now looking for updates on the remaining clinical pipeline for future catalysts. Meanwhile, broader market sentiment remains influenced by recent Eurozone data, which showed the annual inflation rate holding at 3.3% as of early September.